You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Developing therapeutic inhibitors of CIB1 for breast cancer
SBC: Reveris Therapeutics Topic: 102DESCRIPTIONprovided by applicantBreast cancer is the most common malignancy in women living in the USwith more thannew cases diagnosed each yearand an estimatedwomen dying from the disease inGreater thanof these diagnoses are classified as triple negative breast cancerTNBCwhich is considered among the most aggressive breast cancer sub typeswith the worst prognosisTNBC is difficult to treat because ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
GPCR antagonists as anti-Ebola virus entry inhibitors
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
ASTROCYTE ACTIVATION BY SMALL MOLECULE P2Y1 AGONISTS FOR TREATMENT OF TBI
SBC: ASTROCYTE PHARMACEUTICALS INC. Topic: 105DESCRIPTION provided by applicant Traumatic brain injuries TBI are an area of significant unmet need with no approved therapeutics and a national burden of $ billion annually Astrocyte Pharmaceuticals is developing a small molecule pharmaceutical agent that would be administered by intravenous injection by emergency responders or a medical professional within hours of injury to limit n ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Novel filovirus entry inhibitors based on a pseudo-symmetrical biphenyl core
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Ebola EBOV and Marburg MARV viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as biosafety level agents Currently there is no effective vaccine or therapeutic treatment against f ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Lipoprotein synthesis inhibitors for multi-drug resistant Gram-negative therapy
SBC: MICROBIOTIX, INC. Topic: NIAIDDESCRIPTION provided by applicant The increasing prevalence of drug resistant bacterial infections highlights the critical medical need for new agents that are not susceptible to existing resistance mechanisms Few new agents are in development for Gram negative bacteria which take up small molecules sparingly and efflux most compounds that reach the periplasm A particularly problematic group ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Contraceptive testing for semen availability in male monkeys
SBC: EPPIN PHARMA INC Topic: NICHDDESCRIPTION provided by applicant The global contraceptives market was valued at $ billion in and is expected to grow at a CAGR of from to to reach an estimated value of $ billion in An important high impact driver of this market is the prevalence of unintended pregnancies In the US there are million unintended pregnancies annually through inconsistent or ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
New heterocyclic inhibitors of filoviruses
SBC: MICROBIOTIX, INC. Topic: HDESCRIPTION provided by applicant Ebola and Marburg viruses belong to the family Filoviridae and can cause fatal hemorrhagic fevers characterized by widespread tissue destruction with an incubation period of days Because of the safety concerns these viruses are designated as the biosafety level agents Currently there is no effective vaccine or therapeutic treatment against filoviral i ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
New small molecule inhibitors of arenaviruses
SBC: MICROBIOTIX, INC. Topic: RDESCRIPTION provided by applicant Lassa fever virus LASV and Machupo virus MACV are hemorrhagic fever arenaviruses which are classified as Category A Agents Currently there are no licensed LASV or MACV vaccines and LASV MACV therapy is limited to use of the nucleoside analog ribavirin which is only partially effective and associated with significant side effects The impact of arenavirus ...
STTR Phase I 2014 Department of Health and Human ServicesNational Institutes of Health -
A novel drug detection assay using fluorescent biosensor technology
SBC: GLSynthesis Inc. Topic: 300DESCRIPTION provided by applicant This phase project has as its overall objectives to design engineer optimize and implement a novel genetically encoded fluorescent drug sensor FDS based on F rster Resonance Energy Transfer FRET by exploiting conformational rearrangements induced by drug interactions with human serum albumin SA SA is uniquely suited for a general drug sensor beca ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health -
Cloud quantitative imaging for whole-body tumor burden in neurofibromatoses
SBC: IQ MEDICAL IMAGING LLC Topic: 102DESCRIPTION provided by applicant The neurofibromatoses NFs including NF NF and schwannomatosis are a group of autosomal dominant neurogenetic disorders characterized by a predisposition in virtually of patients to develop multiple nerve sheath tumors The determination of tumor burden on magnetic resonance imaging MRI images is crucial for the management of NF patients which is ...
STTR Phase I 2015 Department of Health and Human ServicesNational Institutes of Health